Hospices Civils de Lyon Hopital Femme Mere Enfant
Hospices Civils de Lyon Hopital Femme Mere Enfant
Bron, France4 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, juvenile idiopathic arthritis, musculoskeletal system disorder, rheumatic disorder | Recruiting | Phase 3 | 2026-10-05 | NCT04804553 | |
| A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, endocrine system disorder, hyperparathyroidism, kidney disorder, kidney failure, parathyroid gland disorder, secondary hyperparathyroidism, urinary system disorder | Recruiting | Phase 3 | 2026-08-21 | NCT03969329 | |
| Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease | Behcet disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Oral Ulcer, Skin and Connective Tissue Diseases, Stomatognathic Diseases, anterior uveitis, cardiovascular disorder, eye disorder, hereditary disease, hereditary periodic fever syndrome, hereditary skin disorder, mouth disorder, panuveitis, skin disorder, skin vascular disease, uveal disorder, uveitis, vascular disorder, vasculitis | Recruiting | Phase 3 | 2026-07-24 | NCT04528082 | |
| Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV. | cardiovascular disorder, vascular disorder, vasculitis | Active, not recruiting | Phase 3 | 2026-07-20 | NCT06321601 |